Zogenix (ZGNX) Misses Q4 EPS by 20c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zogenix (ZGNX) Prices 8.52M Share Common Offering at $23/Sh
March 4, 2020 5:56 AM ESTZogenix, Inc. (NASDAQ: ZGNX) announced today that it has priced an underwritten public offering of 8,520,000 shares of its common stock at a price to the public of $23.50 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering... More
Zogenix, Inc. (ZGNX) PT Lowered to $25 at Ladenburg Thalmann
February 28, 2020 7:08 AM ESTLadenburg Thalmann analyst Michael Higgins lowered the price target on Zogenix, Inc. (NASDAQ: ZGNX) to $25.00 (from $35.00) while maintaining a Neutral rating.... More
Zogenix (ZGNX) Announces FDA Extension of Review Period for FINTEPLA in Dravet Syndrome
February 27, 2020 8:06 AM ESTZogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for FINTEPLA® for the treatment of seizures associated with Dravet syndrome. The new Prescription Drug User Fee Act (PDUFA) target... More
